EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies

Alexandros Lazaridis iD, Hector Katifelis iD, Emmanouil Kalampokas iD, Dimitra Lambropoulou, Gerasimos Aravantinos, Maria Gazouli iD, Nikos F Vlahos iD

International Journal of Molecular Sciences · 31.10.2024 · 25 (21) · 11703

DOI: 10.3390/ijms252111703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.10.2024. Verfasst von Alexandros Lazaridis und 6 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Vasilissis Sofias 76, 11528 Athens, Greece. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Genital Neoplasms, Female, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hellenic Society of Medical Oncology (HeSMO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gynecological cancer is a term referring to malignancies that typically involve ovarian, cervical, uterine, vaginal, and vulvar cancer. Combined, these cancers represent major causes of morbidity and mortality in women with a heavy socioeconomic impact. MiRNAs are small non-coding RNAs that are intensively studied in the field of cancer and changes in them have been linked to a variety of processes involved in cancer that range from tumorigenesis to prognosis and metastatic potential. This review aims to summarize the existing literature that has linked miRNAs with each of the female malignancies as potential biomarkers in diagnosis (circulating miRNAs), in tumor histology and prognosis (as tissue biomarkers), and for local (lymph node) and distant metastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorGenital Neoplasms, FemaleMicroRNAsHumansFemalePrognosisNeoplasm MetastasisGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

diagnostic biomarkersendometrial cancermetastatic biomarkersmiRNAsovarian cancervaginal cancervulvar cancer

Substanzen

Biomarkers, TumorMicroRNAs

Autor:innen und Institutionen

  • 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Vasilissis Sofias 76, 11528 Athens, Greece.
  • Laboratory of Biology, Department of Basic Medical Sciences, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, 11527 Athens, Greece.
  • ECONCARE, Chatzigianni Mexi 5, 11528 Athens, Greece.
  • Oncology Department, Euroclinic Athens, Athanasiadou 7-9, 11521 Athens, Greece.

ORCID-Profile: Alexandros Lazaridis, Hector Katifelis, Emmanouil Kalampokas, Maria Gazouli, Nikos F Vlahos

Förderung

  • Hellenic Society of Medical Oncology (HeSMO)

Zitieren

APA

Lazaridis, A., Katifelis, H., Kalampokas, E., Lambropoulou, D., Aravantinos, G., Gazouli, M., & Vlahos, N. F. (2024). Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies. International Journal of Molecular Sciences, 25(21), 11703. https://doi.org/10.3390/ijms252111703

Vancouver

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M, et al. Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies. International Journal of Molecular Sciences. 2024;25(21):11703. doi:10.3390/ijms252111703

BibTeX
@article{Lazaridis2024,
  author = {Lazaridis, Alexandros and Katifelis, Hector and Kalampokas, Emmanouil and Lambropoulou, Dimitra and Aravantinos, Gerasimos and Gazouli, Maria and Vlahos, Nikos F},
  title = {Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {21},
  pages = {11703},
  doi = {10.3390/ijms252111703}
}
Kostenlos starten →